Belite Bio, Inc (BLTE) Earnings
Belite Bio, Inc is expected to report next earnings on August 10, 2026 (in NaN days), with a consensus EPS estimate of $-0.75. BLTE has beaten EPS estimates in 2 of its last 6 reported quarters (average surprise +14.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 20, 2026 | $-0.60 | $-0.34 | +43.3% | — | — |
| Mar 17, 2025 | $-0.30 | $-0.32 | -6.7% | — | — |
| Aug 9, 2024 | $-0.28 | $-0.31 | -10.7% | — | — |
| Mar 11, 2024 | $-0.36 | $-0.25 | +30.6% | — | — |
| Nov 13, 2023 | $-0.31 | $-0.40 | -29.0% | — | — |
| Mar 31, 2023 | $-0.22 | $-1.04 | -374.4% | — | — |
| Sep 29, 2022 | — | $-0.10 | — | — | — |
| Apr 29, 2022 | — | $-0.26 | — | — | — |
| Mar 31, 2022 | — | $-0.05 | — | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 20, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Clinical Development Progress - Received the full Phase 3 clinical study report for Tenabent (for Stargardt disease) in Q1 2026, and initiated rolling New Drug Application (NDA) submission to the FDA in April 2026. The company remains on track to complete submission by Q2 2026. - Completed enrollment in the Phase 2/3 Dragon 2 clinical trial of telurban for Stargardt disease, which enrolled 73 adolescent and adult subjects (ages 12 to 20) across Japan, the U.S., and the U.K. This is a registration-enabling study intended to support approval in Japan. - The company is targeting an interim data readout for its geographic atrophy (GA) indication by the end of 2026. ### Commercial Preparation - All commercial leadership roles have been hired, and the company continues to build out sales, market access, and medical affairs teams. - Commercial infrastructure is under development, and engagement with the retinal medical community is underway to raise disease awareness ahead of launch. ### Overall Strategic Position - 2026 is positioned as a pivotal year for the company's transition from a clinical-stage to a commercial-stage biotech, with a core focus on addressing unmet medical need for retinal degenerative diseases.
Guidance
- The company reaffirmed it will complete the rolling NDA submission for Stargardt disease to the FDA by the end of Q2 2026, with an expected FDA approval in early 2027. - Japan's PMDA is targeting a regulatory approval decision within three months of FDA approval, which the company confirms it remains on track to meet. - The company expects operating expenses to continue increasing gradually as it prepares for commercial launch, due to team expansion and pre-commercial marketing/education activities. Management notes the company's current $799 million cash position is more than sufficient to cover all planned costs: approximately $300 million for U.S. launch of Stargardt disease therapy, plus $150 million for pipeline development over the next three years, for a total expected outlay of $450 million. - An interim data readout for the geographic atrophy indication is targeted for the end of 2026, though the timeline is subject to logistics of data collection and coordination with study sites. - The company plans to share detailed commercial launch and patient uptake projections at a commercial update event planned for September 2026.
Segment performance
Be Light Bio is a pre-commercial clinical-stage biotech focused on retinal disease therapies, so it does not report product revenue across operating segments. The company only reports functional expense categories for this period: 1) Research & Development (R&D): GAAP R&D expenses were $15.7 million in Q1 2026, compared to $9.4 million in Q1 2025. Non-GAAP R&D expenses (excluding share-based compensation) were $13.8 million in Q1 2026, compared to $7.4 million in Q1 2025. The increase was driven by higher spending on the Dragon 2 trial, API and drug product manufacturing, and consultant/professional fees. 2) Selling, General & Administrative (SG&A): GAAP SG&A expenses were $17 million in Q1 2026, compared to $6.1 million in Q1 2025. Non-GAAP SG&A expenses (excluding share-based compensation) were $5.7 million in Q1 2026, compared to $1.5 million in Q1 2025. The increase stemmed from higher share-based compensation, professional service fees, and wages due to team expansion. Total GAAP net loss for Q1 2026 was $26.9 million, versus a $14.3 million net loss in Q1 2025. Non-GAAP net loss (excluding share-based compensation) was $13.7 million in Q1 2026, versus a $7.6 million net loss in Q1 2025. The company ended Q1 2026 with $799 million in cash, cash equivalents, and U.S. Treasury bills, representing a stronger balance sheet than the end of 2025.
Risks & headwinds
- Forward-looking statements regarding clinical trial outcomes, regulatory timelines, approval, and commercial performance are subject to inherent risks and uncertainties, and actual results may differ materially from current expectations. Additional risk factors are detailed in the company's SEC filings. - Interim data readout for GA may be delayed due to the larger size of the trial dataset and logistical coordination with study sites. - There is a remote possibility the FDA could request Dragon 2 trial data for the U.S. NDA approval, which would impact regulatory timelines if it occurs. - All future strategy for the GA indication will depend on unannounced interim data results, so there is uncertainty around development plans and timelines for this program at this stage.
Analyst Q&A
Q: What is the status of Dragon 2 trial data for U.S. FDA approval, and what is the planned size and structure of the commercial sales team given the concentrated Stargardt patient population?
A: Per prior FDA feedback, Dragon 2 data is not required for the U.S. NDA approval, as it is intended solely to meet Japanese regulatory requirements. If the FDA does request Dragon 2 data, interim data will already be available to serve as confirmatory evidence. The company plans two small targeted teams: one for diagnostic outreach and genetic testing awareness, and one for drug promotion, totaling 30-40 members focused on retina specialists, patient advocacy groups, and related care providers. A full commercial update will be shared in September 2026.
Q: What is the timeline and current strategic planning for the geographic atrophy (GA) indication, and what is the approval timeline for Stargardt in Japan?
A: The company is prioritizing U.S. FDA approval for Stargardt disease first, and an interim GA data readout is targeted for the end of 2026. No strategic planning for GA has been finalized because data results are unknown, and all strategy will be data-driven. For Japan, under the SAGIGAKE pioneer pathway, PMDA will issue an approval decision within three months of FDA approval, and the company remains on track for this timeline.
Q: What is the company's filing and launch strategy for ex-U.S. markets including Europe, and what scenarios are possible after the GA interim readout?
A: The company is prioritizing the FDA submission process first to avoid overstretching resources, and ex-U.S. filings will follow FDA completion, aligned with the data and outcomes from the FDA submission. For GA, the most likely scenario after interim data is a study resizing based on observed effect size, with all decisions to be data-driven. The company is committed to bringing therapies to patients globally as quickly as possible, but U.S. Stargardt approval is the immediate focus.
Q: What payer market research has been done on potential pricing for Tenabent, and what is the current level of physician community awareness?
A: Retina specialists are generally aware of Be Light Bio and Tenabent, and are enthusiastic about the first-ever treatment for previously untreatable Stargardt disease as an oral therapy, but in-depth knowledge still needs to be expanded. The company will conduct targeted education at major upcoming ophthalmology conferences through 2026. Payer research supports a reference price range of approximately $350,000 to $500,000, which payers have reacted supportively to, though a final price has not been set.